ECTRIMS 2021 | Serum NfL: a first-in-class biomarker paving the way towards precision medicine in MS

Jens Kuhle, MD, PhD, University Hospital and University of Basel, Basel, Switzerland, shares an overview of the established prognostic value of neurofilament light (NfL) levels in serum or plasma in patients with multiple sclerosis (MS). Technological advancements have enabled simple and rapid detection of NfL in the blood, obviating the need to more invasive cerebrospinal fluid (CSF)-based detection. NfL shows significant promise as an objective biomarker for use in routine MS management and treatment response monitoring, shown to strongly correlate with disease activity. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress 2021.